Leukodystrophies are a broad class of genetic disorders that result in disruption or destruction of central myelination. Although the mechanisms underlying these disorders are heterogeneous, there are many common symptoms that affect patients irrespective of the genetic diagnosis. The comfort and quality of life of these children is a primary goal that can complement efforts directed at curative therapies. Contained within this report is a systems-based approach to management of complications that result from leukodystrophies. We discuss the initial evaluation, identification of common medical issues, and management options to establish a comprehensive, standardized care approach. We will also address clinical topics relevant to select leukodyatrophies, such as gallbladder pathology and adrenal insufficiency. The recommendations within this review rely on existing studies and consensus opinions and underscore the need for future research on evidence-based outcomes to better treat the manifestations of this unique set of genetic disorders.
Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies / L.A. Adang, O. Sherbini, L. Ball, M. Bloom, A. Darbari, H. Amartino, D. Divito, F. Eichler, M. Escolar, S.H. Evans, A. Fatemi, J. Fraser, L. Hollowell, N. Jaffe, C. Joseph, M. Karpinski, S. Keller, R. Maddock, E. Mancilla, B. Mcclary, J. Mertz, K. Morgart, T. Langan, R. Leventer, S. Parikh, A. Pizzino, E. Prange, D.L. Renaud, W. Rizzo, J. Shapiro, D. Suhr, T. Suhr, D. Tonduti, J. Waggoner, A. Waldman, N.I. Wolf, A. Zerem, J.L. Bonkowsky, G. Bernard, K. van Haren, A. Vanderver. - In: MOLECULAR GENETICS AND METABOLISM. - ISSN 1096-7192. - 122:1-2(2017 Sep), pp. 18-32. [10.1016/j.ymgme.2017.08.006]
Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies
D. Tonduti;
2017
Abstract
Leukodystrophies are a broad class of genetic disorders that result in disruption or destruction of central myelination. Although the mechanisms underlying these disorders are heterogeneous, there are many common symptoms that affect patients irrespective of the genetic diagnosis. The comfort and quality of life of these children is a primary goal that can complement efforts directed at curative therapies. Contained within this report is a systems-based approach to management of complications that result from leukodystrophies. We discuss the initial evaluation, identification of common medical issues, and management options to establish a comprehensive, standardized care approach. We will also address clinical topics relevant to select leukodyatrophies, such as gallbladder pathology and adrenal insufficiency. The recommendations within this review rely on existing studies and consensus opinions and underscore the need for future research on evidence-based outcomes to better treat the manifestations of this unique set of genetic disorders.File | Dimensione | Formato | |
---|---|---|---|
2017 linee guida per il follow-up.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
551.33 kB
Formato
Adobe PDF
|
551.33 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.